Transcode Therapeutics Stock Probability of Future Stock Price Finishing Over 43.02
| RNAZ Stock | USD 0.38 0.04 11.76% |
Transcode |
Transcode Therapeutics Target Price Odds to finish over 43.02
The tendency of Transcode Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 43.02 or more in 90 days |
| 0.38 | 90 days | 43.02 | close to zero percent |
Based on a normal probability distribution, the odds of Transcode Therapeutics to move over $ 43.02 or more in 90 days from now is close to zero percent (This Transcode Therapeutics probability density function shows the probability of Transcode Stock to fall within a particular range of prices over 90 days) . Probability of Transcode Therapeutics price to stay between its current price of $ 0.38 and $ 43.02 at the end of the 90-day period is about 65.54 .
Given the investment horizon of 90 days Transcode Therapeutics has a beta of -1.69 indicating as returns on its benchmark rise, returns on holding Transcode Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Transcode Therapeutics is expected to outperform its benchmark. Moreover Transcode Therapeutics has an alpha of 1.2625, implying that it can generate a 1.26 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Transcode Therapeutics Price Density |
| Price |
Predictive Modules for Transcode Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Transcode Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Transcode Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Transcode Therapeutics is not an exception. The market had few large corrections towards the Transcode Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Transcode Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Transcode Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.26 | |
β | Beta against Dow Jones | -1.69 | |
σ | Overall volatility | 0.15 | |
Ir | Information ratio | 0.08 |
Transcode Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Transcode Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Transcode Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Transcode Therapeutics is way too risky over 90 days horizon | |
| Transcode Therapeutics has some characteristics of a very speculative penny stock | |
| Transcode Therapeutics appears to be risky and price may revert if volatility continues | |
| Transcode Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (18.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Transcode Therapeutics currently holds about 13.45 M in cash with (18.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Transcode Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: TransCode Therapeutics gets Nasdaq extension to regain compliance |
Transcode Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Transcode Stock often depends not only on the future outlook of the current and potential Transcode Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Transcode Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 179 K | |
| Cash And Short Term Investments | 2.8 M |
Transcode Therapeutics Technical Analysis
Transcode Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Transcode Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Transcode Therapeutics. In general, you should focus on analyzing Transcode Stock price patterns and their correlations with different microeconomic environments and drivers.
Transcode Therapeutics Predictive Forecast Models
Transcode Therapeutics' time-series forecasting models is one of many Transcode Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Transcode Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Transcode Therapeutics
Checking the ongoing alerts about Transcode Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Transcode Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Transcode Therapeutics is way too risky over 90 days horizon | |
| Transcode Therapeutics has some characteristics of a very speculative penny stock | |
| Transcode Therapeutics appears to be risky and price may revert if volatility continues | |
| Transcode Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (18.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Transcode Therapeutics currently holds about 13.45 M in cash with (18.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Transcode Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: TransCode Therapeutics gets Nasdaq extension to regain compliance |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.